Cargando…

High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer

BACKGROUND: High expression of the RNA-binding motif protein 3 (RBM3) has been shown to correlate, with prolonged survival in several malignant diseases and with the benefit of platinum-based chemotherapy in ovarian cancer. The aim of this study was to evaluate RBM3 in metastatic colorectal cancer (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siesing, Christina, Sorbye, Halfdan, Dragomir, Anca, Pfeiffer, Per, Qvortrup, Camilla, Pontén, Fredrik, Jirström, Karin, Glimelius, Bengt, Eberhard, Jakob
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553773/ https://www.ncbi.nlm.nih.gov/pubmed/28800641 http://dx.doi.org/10.1371/journal.pone.0182512

Ejemplares similares

High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort
por: Sorbye, Halfdan, et al.
Publicado: (2015)

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9
por: Winther, Stine Braendegaard, et al.
Publicado: (2017)

CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup
por: Aasebø, Kristine, et al.
Publicado: (2020)

Consequences of a high incidence of microsatellite instability and BRAF‐mutated tumors: A population‐based cohort of metastatic colorectal cancer patients
por: Aasebø, Kristine Ø., et al.
Publicado: (2019)

Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer
por: Mezheyeuski, Artur, et al.
Publicado: (2016)

Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study
por: Tarpgaard, Line S., et al.
Publicado: (2014)

Let-7 miRNA-binding site polymorphism in the KRAS 3(′)UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/− cetuximab
por: Kjersem, Janne B, et al.
Publicado: (2012)

Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy—The Randomized NORDIC9-Study
por: Liposits, Gabor, et al.
Publicado: (2021)

The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy—The Randomized NORDIC9-Study
por: Liposits, Gabor, et al.
Publicado: (2022)

Lower treatment intensity and poorer survival in metastatic colorectal cancer patients who live alone
por: Cavalli-Björkman, N, et al.
Publicado: (2012)

Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer
por: Thomsen, Maria, et al.
Publicado: (2016)

Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer
por: Ehlén, Åsa, et al.
Publicado: (2010)

Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: An analysis of 215 cases from the Malmö Diet and Cancer Study
por: Jonsson, Liv, et al.
Publicado: (2011)

Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome
por: Thomsen, Maria, et al.
Publicado: (2018)

Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer
por: Mezheyeuski, Artur, et al.
Publicado: (2017)

Delineating the intra-patient heterogeneity of molecular alterations in treatment-naïve colorectal cancer with peritoneal carcinomatosis
por: Siesing, Christina, et al.
Publicado: (2022)

Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study
por: Guren, Tormod Kyrre, et al.
Publicado: (2017)

Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients
por: Pfeiffer, Per, et al.
Publicado: (2009)

A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification
por: Tarpgaard, Line S., et al.
Publicado: (2016)

How to select colorectal cancer patients for personalized therapy
por: Pfeiffer, Per, et al.
Publicado: (2019)

Low RBM3 Protein Expression Correlates with Clinical Stage, Prognostic Classification and Increased Risk of Treatment Failure in Testicular Non-Seminomatous Germ Cell Cancer
por: Olofsson, Sven-Erik, et al.
Publicado: (2015)

TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer
por: Tarpgaard, Line S., et al.
Publicado: (2016)

PRR11 unveiled as a top candidate biomarker within the RBM3‐regulated transcriptome in pancreatic cancer
por: Olsson Hau, Sofie, et al.
Publicado: (2021)

Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab
por: Boisen, Mogens K., et al.
Publicado: (2014)

How to select cancer patients for immunotherapy
por: Pfeiffer, Per, et al.
Publicado: (2021)

The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients
por: Medrek, Catharina, et al.
Publicado: (2012)

Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A/POLAR-M)
por: Pfeiffer, Per, et al.
Publicado: (2022)

Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data
por: Hansen, Torben Frøstrup, et al.
Publicado: (2021)

KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer
por: Osterlund, Emerik, et al.
Publicado: (2022)

Translational study reveals a two-faced role of RBM3 in pancreatic cancer and suggests its potential value as a biomarker for improved patient stratification
por: Karnevi, Emelie, et al.
Publicado: (2017)

A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study
por: Eriksen, Martina, et al.
Publicado: (2022)

Mechanism and Molecular Network of RBM8A-Mediated Regulation of Oxaliplatin Resistance in Hepatocellular Carcinoma
por: Liang, Rong, et al.
Publicado: (2021)

Tumoral ANXA1 Is a Predictive Marker for Sunitinib Treatment of Renal Cancer Patients
por: Niinivirta, Marjut, et al.
Publicado: (2017)

Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib
por: Niinivirta, Marjut, et al.
Publicado: (2017)

Can we predict toxicity and efficacy in older patients with cancer? Older patients with colorectal cancer as an example
por: Winther, Stine Braendegaard, et al.
Publicado: (2016)

High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression
por: Jonsson, Liv, et al.
Publicado: (2011)

Evolutionary Conservation of the Ribosomal Biogenesis Factor Rbm19/Mrd1: Implications for Function
por: Kallberg, Yvonne, et al.
Publicado: (2012)

The Immune Landscape of Colorectal Cancer
por: Mezheyeuski, Artur, et al.
Publicado: (2021)

ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer
por: Magnusson, Kristina, et al.
Publicado: (2016)

Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer
por: Wallin, U, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_iimj8mrka7vs6sp0j6gump8dun